On September 28, 2022, Jonathan Jorgl has filed a definitive proxy statement soliciting proxies and urged the shareholders of AIM ImmunoTech Inc. to vote for Robert L. Chioini and Michael Rice to the Company's board and to vote against the Company's proposal to approve, by non-binding vote, executive compensation at the Company's annual general meeting of shareholders scheduled to be held on November 3, 2022.